FDA Clears 5T Whole-Body MRI System
In addition to enhanced resolution, the uMR Jupiter 5T device reportedly addresses image uniformity and radiofrequency safety that have been previous challenges with ultra-high-field MRI.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the uMR Jupiter 5T system, the first ultra-high-field magnetic resonance imaging (MRI) system to gain clearance for full-body exams.
Equipped with an eight-channel whole-body multi-transmit system, the uMR Jupiter 5T system bolsters the clarity and detail of anatomical structures, according to United Imaging, the manufacturer of the device. The company said the 5T MRI system offers enhanced imaging capabilities for the heart, abdomen and pelvis that will facilitate improved diagnostic precision.
Reportedly the first ultra-high-field magnetic resonance imaging (MRI) system to gain FDA clearance for full-body exams, the uMR Jupiter 5T system offers enhanced imaging capabilities for the heart, abdomen and pelvis that may facilitate improved diagnostic precision. (Image courtesy of United Imaging.)
In addition to improved visualization of challenging anatomical regions, United Imaging noted that the device’s design and technology address previous issues associated with ultra-high-field MRI by ensuring radiofrequency safety and consistent imaging quality.
“We have always prioritized innovation that can make a broad clinical impact. Because it is aimed first and foremost at bringing ultra-high-field into greater clinical use, we believe (the uMR Jupiter 5T system) will have an exciting impact across our industry, and for clinical patients across the globe who have never had access to ultra-high-field in the past,” noted Jeffrey M. Bundy, Ph.D., the president and chief commercial officer of United Imaging in North America.
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.
FDA Clears MRI-Based AI Segmentation of Organs at Risk During Radiation Therapy
May 2nd 2025Capable of segmenting over 37 organs and structures in the head, neck and pelvis, the MR Contour DL software is currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference.
